Bayer receives FDA accelerated approval for HER2-mutant lung cancer drug
Bayer received FDA accelerated approval for sevabertinib as a first-line treatment for advanced HER2-mutant non-small cell lung cancer patients, after priority review and breakthrough therapy status.
Bayer received accelerated approval from the Food and Drug Administration for its treatment of non-small cell lung cancer. The FDA approved sevabertinib as a first-line treatment for patients with advanced HER2-mutant lung cancer, following a priority review and breakthrough designation.